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Abstract
Background: Carotid endarterectomy (CEA) is a beneficial procedure for selected patients with an internal carotid
artery (ICA) stenosis. Surgical risk of CEA varies from between 2 and 15%.
The aim of the study is to demonstrate the safety and effectiveness of sonolysis (continual transcranial Doppler
monitoring, TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy on the reduction of the
incidence of stroke, transient ischemic attack (TIA) and brain infarction detected using magnetic resonance imaging
(MRI) by the activation of the endogenous fibrinolytic system during CEA.
Methods/design: Design: a multicenter, randomized, double-blind, sham-controlled trial.
Scope: international, multicenter trial for patients with at least 70% symptomatic or asymptomatic ICA stenosis
undergoing CEA.
Inclusion criteria: patients with symptomatic or asymptomatic ICA stenosis of at least 70% are candidates for CEA; a
sufficient temporal bone window for TCD; aged 40–85 years, functionally independent; provision of signed
informed consent.
Randomization: consecutive patients will be assigned to the sonolysis or control (sham procedure) group by
computer-generated 1:1 randomization. Prestudy calculations showed that a minimum of 704 patients in each
group is needed to reach a significant difference with an alpha value of 0.05 (two-tailed) and a beta value of 0.8
assuming that 10% would be lost to follow-up or refuse to participate in the study (estimated 39 endpoints).
Endpoints: the primary endpoint is the incidence of stroke or TIA during 30 days after CEA and the incidence of
new ischemic lesions on brain MRI performed 24 h after CEA in the sonolysis and control groups. Secondary
endpoints are occurrence of death, any stroke, or myocardial infarction within 30 days, changes in cognitive
functions 1 year post procedure related to pretreatment scores, and number of new lesions and occurrence of
new lesions ≥0.5 mL on post-procedural brain MRI.
Analysis: descriptive statistics and linear/logistic multiple regression models will be performed. Clinical relevance will
be measured as relative risk reduction, absolute risk reduction and the number needed to treat.
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Discussion: Reduction of the periprocedural complications of CEA using sonolysis as a widely available and cheap
method may significantly increase the safety of CEA and extend the indication criteria for CEA.
Trial registration: ClinicalTrials.gov, NCT02398734. Registered on 20 March 2015.
Keywords: Sonolysis, Stroke, Carotid, Endarterectomy, Brain infarction
Background
Stroke is the third most common cause of death in the
majority of the developed countries [1]. This has also been
so in the Czech Republic for many years – approximately
7000 men and 10,000 women die of stroke each year [2].
Stroke in the Czech Republic has even double the inci-
dence than the remainder of Western Europe. Internal ca-
rotid artery (ICA) stenosis is one of the most common
etiological factors of ischemic stroke, causing 10–35% of
strokes [3].
Stroke risk increases with the increased severity of ICA
stenosis and this risk is higher in symptomatic stenoses
than in asymptomatic ones. Results of the NASCET [4],
ECST [5] and ACAS [6] studies have shown that carotid
endarterectomy (CEA) represents a beneficial pro-
cedure for patients with a symptomatic ICA stenosis
of >50% and for patients with an asymptomatic ICA
stenosis >60% [7]. Perioperative risk of transient is-
chemic attack (TIA), stroke, myocardial infarction or
death for CEA varies between 2 and 15% [3, 8].
However, even clinically silent microembolism can
cause microinfarctions presenting with postoperative
cognitive deficit [9]. Carotid artery stenting represents
another treatment possibility in these patients and patients
with contraindications to CEA or high-risk patients are
the main candidates for carotid artery stenting [7, 10].
Nevertheless, CEA remains the “gold standard” for ICA
stenosis treatment [11].
Since the 1970s, in-vitro and animal model studies
have demonstrated acceleration of thrombus dissolution
using an ultrasound beam. Studies with many animal
models (e.g., rabbits, rats) showed acceleration of spon-
taneous or pharmacologically induced thrombolysis
using ultrasound beam with frequencies ranging be-
tween 20 kHz and 2 MHz [12–14].
Alexandrov et al. cited a large number of early arterial
recanalizations in acute stroke patients with middle
cerebral artery (MCA) occlusion who were treated using
systemic thrombolysis in combination with transcranial
Doppler (TCD) monitoring [15].
Between 2002 and 2005, three other studies demon-
strated the potential effect of diagnostic ultrasound on the
acceleration of spontaneous or induced recanalization of
intracranial arteries [16–18]. This therapeutic procedure is
called sonolysis or thrombotripsy when ultrasound moni-
toring is used alone or sonothrombolysis when ultrasound
monitoring is used in combination with thrombolytics.
There are two possible effects of ultrasound on thrombus:
(1) mechanical destruction due to vibration of the
thrombus with acceleration of penetration of fibrinolytics
into the thrombus and (2) elevation of temperature and
stimulation of endothelium with local activation of the fi-
brinolytic system [16–21]. A recent study showed that
TCD monitoring had a significant effect on activation of
the fibrinolytic system in healthy volunteers [22].
TCD monitoring during CEA is a common diagnostic
method being used for the detection of microemboli and
changes of blood flow in intracranial stenoses [23]. Re-
duction of periprocedural complications of CEA with
TCD monitoring was mentioned in some studies. This
reduction of stroke risk could be due to the sophisti-
cated indications for shunt implementation, optimization
of surgery and anesthesia according to the blood flow
changes, and the detection of microemboli in the MCA
using TCD monitoring [23]. Another cause of the reduc-
tion of microinfarctions is the local activation of the en-
dogenous fibrinolytic system due to TCD monitoring
(equal to sonothrombolysis in acute stroke studies) [21].
The recently published SONOBUSTER trial showed that
intraoperative sonolysis reduced both the incidence and
the volume of new brain infarctions following CEA.
These benefits were most evident for larger infarctions
(volume ≥0.5 mL) and extended beyond the region dir-
ectly exposed to ultrasonic waves (i.e., the contralateral
hemisphere) [22]. However, the effect on cognitive func-
tion decline was not significant in this study due to the
low number of patients involved [22].
Methods/design
Study objectives
The objective of this multicenter, randomized, double-
blind, sham-controlled study is to demonstrate the safety
and effectiveness of sonolysis (continual TCD monitor-
ing), using a 2-MHz diagnostic probe with a maximal
diagnostic energy, on the reduction of the incidence of
stroke, TIA and brain infarction by activation of the en-
dogenous fibrinolytic system during CEA in patients with
≥70% symptomatic or asymptomatic stenosis of the ICA.
The substudy aims to compare the risk of brain infarc-
tion detected using magnetic resonance imaging (MRI)
between the sonolysis and the control group.
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Overview
The SONOBIRDIE trial is a randomized, double-blind,
sham-controlled study designed to demonstrate the safety
and effectiveness of sonolysis (continual TCD monitoring)
in reduction of the risk of stroke or TIA, brain infarction
and cognitive decline using a 2-MHz diagnostic probe
with a maximal diagnostic energy on the reduction of the
risk of brain infarction by the activation of endogenous
fibrinolytic system during CEA in patients with ≥70%
symptomatic or asymptomatic ICA stenosis (Table 1).
Ethical approval of the study protocol
The study is conducted in accordance with the Declar-
ation of Helsinki of 1975 (as revised in 2004 and 2008)
and approved by the multicenter Ethics Committee of
Vítkovice Hospital and local Ethics Committees of all
participating centers. All patients provide written in-
formed consent before enrollment. The study design




The sample size is based on an expected 2.5% absolute
risk reduction of stroke or TIA incidence during the 30-
day postoperative period in the sonolysis group (esti-
mated prevalence, 1.5%) compared to the control group
(estimated prevalence, 4%). Prestudy calculations showed
that a minimum of 704 patients in each group is needed
to reach a significant difference with an alpha value of
0.05 (two-tailed) and a beta value of 0.8 assuming that
10% would be lost to follow-up or refuse to participate
in the study (estimated 39 endpoints).
Due to the higher sensitivity of MRI in the detection
of new brain ischemic lesions, the sample size for the
MRI substudy was based on an expected 15% reduction
of new ischemic lesions on diffusion-weighted imaging-
magnetic resonance imaging (DWI-MRI) in the sonolysis
group (estimated prevalence, 10%) compared to the con-
trol group (estimated prevalence, 25%). Prestudy calcula-
tions showed that a minimum of 124 patients
undergoing brain MRI in each group was needed to
reach a significant difference with an alpha value of 0.05













(30 ± 2 days after
CEA)
Visit 5




X X X X X
Demographics X
Physical examination X X X X X
Vital signs X X X
Neurological
examination
X X X X X
NIHSS X X X X X
mRS X X X X X
Duplex sonography X X X X X







X X (24 ± 4 h)
ACE-R X X X X
MMSE X X X X
Clock-drawing Test X X X X
Verbal Fluency Test X X X X
Sonolysis X
Sham procedure X
Adverse event, SAE X X X
Endpoints X X X
ACE-R Addenbrooke’s Cognitive Examination Revised, CEA carotid endarterectomy, CTA computed tomography angiography, DSA digital subtraction angiography,
MMSE Mini Mental State Examination, MRA magnetic resonance angiography, MRI magnetic resonance imaging, mRS modified Rankin score, NIHSS National
Institutes of Health Stroke Scale, SAE serious adverse event
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(two-tailed) and a beta value of 0.8 assuming that 10%
would be lost to follow-up or refuse to participate in the
MRI substudy.
Inclusion criteria
1. Subject has a symptomatic or asymptomatic ICA
stenosis ≥70% using NASCET criteria as detected by
a duplex sonography and confirmed using computed
tomography angiography (CTA), magnetic
resonance angiography (MRA) or digital subtraction
angiography (DSA) [4]
2. Subject has indications for CEA according to the
criteria set by the American Heart Association/
American Stroke Association and Czech
guidelines [7, 24]
3. Subject is aged 40–85 years
4. Subject has a sufficient temporal bone window for
TCD with detectable blood flow in the MCA
5. Subject is functionally independent with a modified
Rankin score (mRS) value of 0–2 points
6. Informed consent is signed by the subject
Exclusion criteria
1. Subject has been participating in another clinical
trial within last 6 weeks
2. Subject has any other medical condition that would
make them inappropriate for study participation in
the opinion of the investigator
Substudy
All patients who fulfill the main study criteria and will
have no contraindication to MRI (e.g., pacemaker in situ,
implanted metal material, claustrophobia) will be en-
rolled in the MRI substudy until 124 patients have been
assigned to each group.
Test device
The TCD systems (e.g., DWL Multi-Dop T1, DWL, Sip-
plingen, Germany) with a diagnostic 2-MHz probe will
be used for sonolysis (nondiagnostic TCD monitoring).
Sonolysis
In patients randomized into the sonolysis group, a MCA
segment to a depth of 55 mm will be continuously mon-
itored during intervention using a diagnostic 2-MHz
TCD probe with a maximal diagnostic energy (Thermal
Index for cranial bone (TIC) approximately 1.3) and a
sample volume of 10 mm. The probe will be fixed in the
required position using a special helmet and sonolysis
will start before the carotid intervention and will be
stopped after the intervention, but at latest after
120 min. A TCD machine (DWL MultiDop T1, DWL
Elektronische Systeme Sipplingen, Germany) with a 2-
MHz diagnostic TCD probe will be used. This nondiag-
nostic TCD monitoring will be performed with recording
of microembolic signals and changes in blood flow. Device
sound and Doppler wave imaging will be switched off.
Only the sonographer will be unblinded to the procedure.
Sham procedure
In patients randomized into the control group, the TCD
probe will be fixed in the required position using a spe-
cial helmet as in sonolysis group patients, but a MCA
segment to a depth of 55 ± 5 mm will be localized using
a diagnostic 2-MHz transcranial TCD probe with a max-
imal diagnostic energy and the TCD monitoring will be
stopped afterwards. Patients in the control group will
undergo a sham procedure in which further sonolysis
(TCD monitoring) will not be conducted.
Carotid endarterectomy
Surgery will be performed under general or local
anesthesia (the decision will be left to the discretion of
the operating team) using an incision in front of the
angle of the sternomastoid muscle. The common carotid
artery and later the ICA and the external carotid artery
will be mobilized. The common carotid artery, the ICA
and the external carotid artery will be temporarily
closed. Using a longitudinal incision of the common ca-
rotid artery and the ICA, atherosclerotic plaque will be
visualized. Plaque will be withdrawn under microscopic
control and later an arteriotomy suture will be per-
formed using a monofilament nonabsorbent 6/0 fiber.
Just before the end of surgery, hemostasis will be
achieved and a drainage mechanism applied. Surgery will
be completed by suture of subcutis and cutis. Unfractio-
nated heparin (100 IU/kg bodyweight) may be adminis-
tered to all patients just before the arteriotomy. In the
case of insufficient collateral flow into the MCA after
clipping of the common carotid artery and the ICA, a
temporal shunt may be used. Antiplatelet therapy (clopi-
dogrel 75 mg/day or acetylsalicylic acid 100 mg/day) will
be used continuously in all patients. The surgeon will be
blinded to the sonolysis or sham procedures.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) will be performed in
patients enrolled in the MRI substudy. The MRI protocol
consists of four sequences: (1) transverse T2-weighted
spin echo (echo time, 100 ms; repetition time, 4310 ms;
section thickness, 5.0 mm; matrix size, 192 × 256; gap,
0.5 mm; field of view (FOV), 250 mm; FOV ph, 75%; echo
train length (ETL), 9; number of excitations, 1); (2)
diffusion-weighted imaging (echo time, 130 ms; repetition
time, 4500 ms; b, representing a factor of diffusion-
weighted sequences b = 0 and b = 1,000 s/mm2; section
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thickness, 5.0 mm; gap, 1 mm; matrix size, 192 × 192;
FOV, 255 mm; FOV ph, 100%; number of excitations, 4;
echo spacing, 0.93 ms; bandwidth, 1240 Hz/Px); apparent
diffusion coefficient maps will be obtained in all cases; (3)
T2 star-weighted gradient-recalled echo (GRE) sequence
for detection of bleeding (including microbleeds); (4)
fluid-attenuated inversion recovery (FLAIR; echo time,
109 ms; repetition time, 8000 ms; inversion time, 2500 ms;
section thickness, 5.0 mm; matrix size, 256 × 151; gap,
0.5 mm; FOV, 250 mm; FOV ph, 77%; number of excita-
tions, 1; ETL, 5). Sequences will be applied at an identical
level with the same slice thickness and identical cut num-
ber. Slice thickness will comprise the cut thickness
(5 mm) + gap (10%). The standard number of slices will be
25. The standard slice level will be considered to be a
modified level of the skull base due to minimalization of
the distant-artifacts’ echo planar imaging (EPI) sequence.
In accordance with previous studies [22, 25–29], a
new ischemic brain lesion is defined as hyperintense
regions on the post-intervention DWI that were not
present on pretreatment images. The volume of new
brain infarctions will be measured manually. Infarct
volumes will be calculated as the total hyperintense area
in single slices multiplied by an effective slice thickness:
Actual slice thicknessþ Distance factorð Þ=Interslice gap½ :
Ischemic lesions in the brain will be evaluated by two
blinded investigators. All disagreements will be resolved
by consensus. The third blinded investigator will be in-
volved in a case of a persistent disagreement. Ischemic
lesions <0.5 mL or ≥0.5 mL will be evaluated separately
in the subanalyses. New ischemic lesions in the brain
will be classified as ipsilateral or contralateral to the
treated vessel. Enlargement of a previous DWI lesion
will be not considered a new ischemic lesion.
Clinical examinations
Standard physical and neurological examinations will be
performed before CEA, 24 h, 30 days and 1 year after
CEA. Evaluation of the neurological deficit will be per-
formed using the National Institutes of Health Stroke
Scale (NIHSS) and mRS before CEA, 24 h, 30 days and
1 year after CEA.
Cognitive tests
Cognitive testing (Addenbrooke’s Cognitive Examination
Revised (ACE-R), the Mini Mental State Examination
(MMSE), the Clock-drawing Test, the Verbal Fluency
Test) will be performed before, 24 h, 30 days and 1 year
after CEA.
The MMSE will be used to assess orientation, registra-
tion (immediate memory), short-term memory and lan-
guage functioning. It includes 30 questions. One point
will be given for each correct answer. The total results
may range from 0 points as minimum to 30 points as
maximum.
The Clock-drawing Test will be used for a brief
cognitive task testing of executive functioning (memory,
concentration, initiation, energy, mental clarity and indeci-
sion). Errors in clock-drawing will be evaluated: omissions,
perseverations, rotations, misplacements, distortions, sub-
stitutions and additions. The Shulman scoring system (0–5
points) will be used for test result evaluation.
The Verbal Fluency Test will be used to test executive
functioning and linguistic skills. Participants will be asked
to say as many words beginning with the letter “P” as
possible from a given category within 60 s. This will be
scored from 0 to 7 points: 0–1 words, 0 points; 2–3 words,
1 point; 4–5 words, 2 points; 6–7 words, 3 points; 8–10
words, 4 points; 11–13 words, 5 points; 14–17 words,
6 points; and more than 17 words, 7 points.
All cognitive tests will be performed by a blinded
investigator.
Randomization
Consecutive patients will be assigned to the sonolysis or the
control group by computer-generated 1:1 randomization.
Data source
Datasets for analysis collected during visits will consist of:
A. Demographic data
1. Age (years)
2. Gender (male or female)
3. Arterial hypertension (diagnosed)
4. Diabetes mellitus (diagnosed)
5. Coronary heart disease (diagnosed)
6. Atrial fibrillation (diagnosed)
7. Hyperlipidemia (diagnosed)
8. Statin type
9. Statin dose (milligrams per day)
10.Smoking (number of cigarettes per day)
11.Alcohol abuse (number of units per day)
12.Antithrombotics (type)
13.Antithrombotics (dose: milligrams per day)
B. Sonographic/computed tomography/angiography
data
1. Side of carotid stenosis
2. Severity (%) of the intervened carotid stenosis –
duplex sonography
3. Severity (%) of the intervened carotid stenosis –
CTA (NASCET)
4. Severity (%) of the contralateral carotid stenosis –
duplex sonography
5. Severity (%) of the contralateral carotid stenosis –
CTA (NASCET)
6. Plaque characteristics
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C. Intervention data
1. Type of anesthesia (local, general)
2. Time from symptom onset to intervention
3. Sonolysis
4. Duration of sonolysis
5. Plaque extraction feasibility
6. Shunt use
D. Clinical data (at visits 1, 2, 3, 4 and 5)
1. NIHSS score
2. mRS score
E. MRI data – endpoints (at visit 3)
1. New brain infarction on DWI-MRI
2. New brain infarction on DWI-MRI ipsilateral to
the intervention
3. New brain infarction with a total volume
≥0.5 cm3 (mL)
F. Cognitive tests data (at visits 2, 3, 4 and 5)
1. MMSE result
2. Clock-drawing Test result
3. Verbal Fluency Test result
4. ACE-R results
G. Clinical endpoints (at visits 3 and 4)
1. Ischemic stroke or TIA within 30 days after the
intervention
2. Death within 30 days after the intervention
3. Any stroke within 30 days after the intervention
4. Myocardial infarction within 30 days after the
intervention
H. Adverse events (at visits 3, 4 and 5)
1. Adverse event during carotid intervention
2. Adverse event during first 24 h after carotid
intervention (e.g., worsening of neurological
symptoms by ≥4 points in the NIHSS, brain
edema, symptomatic and asymptomatic
intracranial bleeding detected on control brain
DWI-MRI)
3. Adverse event during 30 days after carotid
intervention (e.g., new admissions to the hospital,
worsening of neurological symptoms by ≥4 points
in the NIHSS)
I. Medication (at all visits)
1. Antiplatelet therapy (generic name, daily dose)
2. Anticoagulants (generic name, daily dose)
3. Statin (generic name, daily dose)
4. Antihypertensives (generic name, daily dose)
5. Insulin
6. Oral hypoglycemic agents
7. Others
Analysis sets
Efficacy analyses will be performed primary for the
intent-to-treat population. The secondary analysis will
be performed also for the per-protocol population. The
intent-to-treat population will consist of all randomized
subjects who signed informed consent. The per-protocol
population will exclude all subjects in the intent-to-treat
population who:
1. Have not undergone CEA
2. Have not received sonolysis during carotid CEA for
at least 40 min
3. Have not attended one of the last 3 visits – visit 3
(24 h after CEA), visit 4 (30 days after CEA) or visit
5 (1 year after CEA)
Safety analyses will be performed on all randomized
subjects undergoing the carotid intervention.
Efficacy and safety endpoints
Primary efficacy endpoints:
1. Incidence of stroke or TIA during 30 days after the
CEA in the sonolysis and control groups
2. For the MRI substudy: the incidence of new
ischemic lesions on brain DWI-MRI performed
24 h after the CEA in the sonolysis and control
groups
Secondary efficacy endpoints:
1. Occurrence of death, any stroke, or myocardial
infarction within 30 days (myocardial infarction is
defined as a post-interventional cardiac troponin
T level increase of more than twice the normal
upper limit in addition to either chest pain, symp-
toms consistent with cardiac ischemia, or electro-
cardiographic evidence of ischemia)
2. Changes in cognitive functions as evidenced by
ACE-R, MMSE, Clock-drawing Test or Verbal Fluency
Test scores 1 year post procedure relative to
pretreatment scores
3. Changes in cognitive function as evidenced by ACE-
R, MMSE, Clock-drawing Test or Verbal Fluency
Test scores 24 h and 30 days post procedure relative
to pretreatment scores
4. For the MRI substudy: number of new lesions and
occurrence of new lesions ≥0.5 mL on post-
procedural brain DWI-MRI
5. For the MRI substudy: incidence of ipsilateral new
ischemic lesions on post-procedural brain DWI-
MRI
Safety endpoints:
1. Safety will be evaluated with a summary of adverse
events
2. Incidence of intracranial bleeding (including brain
microbleeds) on T2 star-weighted GRE-MRI
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Statistical methods
The normality of distribution of all proceeded data will
be checked using the Shapiro-Wilk test. Data with a nor-
mal distribution will be reported as the mean ± standard
deviation. Parameters not fitting a normal distribution
will be presented as the mean, median and interquartile
range. Categorical variables in the two arms will be com-
pared by Fisherʼs exact test. Continuous variables will be
compared by the Studentʼs t test for normally distrib-
uted values, or the Mann-Whitney U test. Spearman
correlation coefficient and intraclass correlation coeffi-
cient will be calculated for the evaluation of interob-
server and intraobserver agreements of brain infarction
volume measurement. Multiple logistic regression ana-
lyses will be used to determine the possible predictors of
stroke or TIA, cognitive decline, or a new brain infarc-
tion. All tests will be carried out at a 0.05 alpha level of
significance. All statistical tests will be performed at the
Department of Biophysics, Informatics and Biometry,
Faculty of Medicine and Dentistry, Palacký University,
Olomouc.
Collection of data to study database
All data will be collected by investigators during patients’
visits from the patient database and from the hospital elec-
tronic database. Only the investigators who will perform
the randomization and/or sonolysis/sham procedure will
add all patient data to the electronic REDCap database
(https://kcentsrv.fnmotol.cz/redcap/redcap_v6.9.3/index.
php?pid=16). This database will be used to generate tables
and results to be executed by a statistician and will contain
only encrypted information about the allocation group for
each patient to maintain allocation concealment.
Allocation concealment
Randomization and allocation to sonolysis or the sham
procedure will be performed by the sonographer perform-
ing sonolysis or the sham procedure after the baseline
visit. All randomized patients, neurologists performing
neurological examinations at the baseline visit (visit 1) and
control visits (visits 2, 3, 4 and 5), investigators performing
cognitive tests at subsequent visits (visits 2, 3, 4 and 5),
surgeons performing CEA and radiologists performing
brain MRI will be blinded to allocation (sonolysis or the
sham procedure).
Adverse events
Adverse events (AEs) will be recorded for enrolled
participants at any visit, including unscheduled visits.
AEs are classified according to their relationship to the
device and/or procedure and according to severity. All
AEs, regardless of the reason or severity, are followed
with appropriate corrective actions by the investigators
until a satisfactory resolution is obtained. All AEs will be
reported to the local Ethics Committee (Institutional Re-
view Board) and the State Institute for Drug Control.
Dissemination plan
The trial protocol was written following the Reco-
mmendations for Interventional trials (SPIRIT) Checklist
(see Additional file 1). Schedule of enrolment, interven-
tions and assessments are displayed in the Figure 1. The
study findings will be reported according to the Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines (see Additional file 2). Protocol modifications will be
reported when disseminating findings. Authorship of
scientific articles emerging from the study will be decided
upon by the International Committee of Medical Journal
Editors’ guidelines.
Discussion
The indications and safety of CEA and carotid stenting are
still important and serious current topics, especially indica-
tions and safety of both methods. Thus, more studies are
needed in this field. The optimal treatment procedure and
medical management to avoid brain lesions during carotid
revascularization is still under research [30].
Three recent meta-analyses concluded that sonolysis
was a promising treatment for patients who have suf-
fered from acute ischemic stroke [20, 31, 32]. Further-
more, the SONOBUSTER trial has demonstrated the
effect of intraoperative sonolysis on the reduction of the
prevalence and volume of new brain ischemic lesions
after CEA and carotid stenting [22]. Results of the
SONORESCUE trial have also demonstrated a significant
reduction in the prevalence of larger new ischemic lesions
and lesion volume in the brain after cardiac surgery [29].
The possible usability of sonolysis in the prevention of
brain lesions during carotid revascularization was
highlighted in the recently published review paper “The
year in cardiology 2015: peripheral circulation” [30].
The mechanisms of sonolysis in the present study in-
clude acceleration of enzymatic fibrinolysis by the direct
activation of a fibrinolytic system and increased trans-
port of fibrinolytic agents (e.g., plasmin) into the
thrombus by mechanical disruption of thrombus struc-
ture, destruction of gaseous bubbles, and transient per-
ipheral vasodilatation [12–22, 29, 31, 32].
The study results will be important not only for the
possible reduction of clinical vascular events, silent brain
infarction or cognitive decline after CEA, but should
also improve the understanding of the sonolysis mecha-
nisms that accelerate fibrinolysis.
Study limitations
Serial follow-up FLAIR and DWI-MRI will not be con-
ducted to compare the progression or persistence of ische-
mic lesions. The cognitive test battery is limited to ACE-
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R. A more expanded neuropsychological battery would be
more sensitive for the detection of specific cognitive im-
pairment, but would be more time-consuming. This might
also increase the risk of participants refusing to continue
in the study or to complete the full battery, especially
shortly after the surgery.
Trial status
At the time of manuscript submission, 137 participants in
13 European centers have been recruited to the trial and it
remains open to recruitment. The study was approved by
the multicenter Ethics Committee of Vítkovice Hospital
and local Ethics Committees of all participating centers
(Ethics Committee of the University Hospital Ostrava,
Ethics Committee of the Military University Hospital
Prague, Ethics Committee of the University Hospital
Motol, Ethics Committee of the Na Homolce Hospital,
Ethics Committee of the Faculty Hospital Nitra, Ethics
Committee of the University Hospital Martin, Ethics
Committee of the Liberec Hospital, Ethics Committee of
the České Budějovice Hospital, Ethics Committee of the
T. Baťa Hospital, Ethics Committee of the University
Hospital Plzeň, Ethics Committee of the University
Hospital Hradec Králové and Ethics Committee of the
Jihlava Hospital).
Additional files
Additional file 1: SPIRIT Checklists with recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
Additional file 2: CONSORT 2010 Checklist of information to include
when reporting a randomized trial. (DOC 218 kb)
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Endarterectomy trial; SONORESCUE: The Sonolysis in Prevention of Brain
Infarction during Cardiac Surgery trial; TCD: Transcranial Doppler monitoring;
TIA: Transient ischemic attack; TIC: Thermal Index for cranial bone
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